The pathway to successfully commercializing a life sciences product can often be protracted and complicated. As any seasoned legal professional in the industry knows, the journey begins with extensive research and development, which can last for years. The culmination of this work is then subject to rigorous clinical trials and testing, a process designed to ensure the safety and efficacy of the product for its intended users. No life sciences product can reach the market without the vital stamp of approval from the Food and Drug Administration (FDA).
However, while the FDA approval is a significant milestone, it by no means signals the end of the complexities involved in commercialization. Rather than marking the conclusion of the journey, achieving FDA approval merely allows the journey to transform into a new phase. Now, businesses are tasked with successfully commercializing their products whilst navigating a minefield of varying exposures. Managing these potential hazards is crucial to ensuring the smooth and prosperous rollout of a life sciences product.
While much has been written on this subject, it is worth referring to an insightful piece from Woodruff Sawyer. This piece delves into the nuances of managing exposures during commercialization, providing businesses and legal professionals alike with useful strategies to consider on the path to successfully bringing a life science product onto the market. It serves as a worthy read for any legal professionals dealing with life science products, from in-house legal teams at multinational pharmaceutical companies to boutique firms that specialize in life sciences.